Activity Overview
This online, on-demand virtual symposium brings together renowned experts in psychiatry. In this educational program, these experts discuss emerging data on the treatment of tardive dyskinesia (TD) with a forward-looking perspective on how novel agents might impact clinical practice. Discussions regarding early disease identification are also included in this activity.
This educational activity is an archive of the live virtual symposium held on October 2, 2026.
System requirements for this online activity are available here.
The activity is free to all users.
Target Audience
This educational activity is directed toward psychiatrists, psychiatric nurse practitioners, physician assistants, registered nurses, pharmacists, and other health care providers involved in the management of patients with TD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement strategies to identify patients with TD
- Differentiate between the characteristics of different therapies for TD
- Design individualized management plans for patients with TD
Jose M. Rubio, MD, PhD
Assistant Professor of Psychiatry
Institute of Behavioral Science
Feinstein Institutes for Medical Research
Glen Oaks, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Bristol Myers Squibb, Karuna, Teva; Grant/Research Funding (to institution): Alkermes, Neurocrine, Saladax; Royalty or Patent Benefits: UpToDate
Erin Crown, MHS, PA-C, Psych-CAQ
Managing Member
Oasis LifeCare
State College, PA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Axsome Therapeutics, Boehringer Ingelheim, Intra-Cellular Therapies, Johnson & Johnson, Lundbeck, Neurocrine Biosciences, Otsuka, Supernus; Speakers Bureau: Axsome Therapeutics, Intra-Cellular Therapies, Johnson & Johnson, Lundbeck, Neurocrine, Otsuka, Supernus; Grant/Research Funding (to institution): Boehringer Ingelheim, Click Therapeutics, Johnson & Johnson, Relmada Therapeutics Inc
John J. Miller, MD
Editor-in-Chief, Psychiatric Times®
Medical Director, Brain Health
Exeter, NH
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Axsome, Boehringer Ingelheim, Intra-Cellular Therapies, Karuna/Bristol Myers Squibb; Speakers Bureau: AbbVie, Axsome, Bristol Myers Squibb, Intra-Cellular Therapies, Johnson & Johnson/Janssen, Neurocrine, Otsuka/Lundbeck, Teva
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians Education Resource®, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for a maximum of 1.0 contact hour (1.0 CEU) under UAN # 0661-0000-26-030-H01-P. This UAN # expires 01/31/2028.
Eligibility for credits requires full engagement with the enduring activity, completion of the post-activity assessment questions, completion and submission of the activity evaluation, NABP e-pid # and month/date of birth within 30 days of activity completion. No partial credits are given.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.